The anticancer effects of HDAC inhibitors require the immune system

Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFN...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Alison C, Smyth, Mark J, Johnstone, Ricky W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962507/
https://www.ncbi.nlm.nih.gov/pubmed/24701376
http://dx.doi.org/10.4161/onci.27414
_version_ 1782308451193454592
author West, Alison C
Smyth, Mark J
Johnstone, Ricky W
author_facet West, Alison C
Smyth, Mark J
Johnstone, Ricky W
author_sort West, Alison C
collection PubMed
description Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
format Online
Article
Text
id pubmed-3962507
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39625072014-04-03 The anticancer effects of HDAC inhibitors require the immune system West, Alison C Smyth, Mark J Johnstone, Ricky W Oncoimmunology Author's View Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic. Landes Bioscience 2014-01-01 /pmc/articles/PMC3962507/ /pubmed/24701376 http://dx.doi.org/10.4161/onci.27414 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
West, Alison C
Smyth, Mark J
Johnstone, Ricky W
The anticancer effects of HDAC inhibitors require the immune system
title The anticancer effects of HDAC inhibitors require the immune system
title_full The anticancer effects of HDAC inhibitors require the immune system
title_fullStr The anticancer effects of HDAC inhibitors require the immune system
title_full_unstemmed The anticancer effects of HDAC inhibitors require the immune system
title_short The anticancer effects of HDAC inhibitors require the immune system
title_sort anticancer effects of hdac inhibitors require the immune system
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962507/
https://www.ncbi.nlm.nih.gov/pubmed/24701376
http://dx.doi.org/10.4161/onci.27414
work_keys_str_mv AT westalisonc theanticancereffectsofhdacinhibitorsrequiretheimmunesystem
AT smythmarkj theanticancereffectsofhdacinhibitorsrequiretheimmunesystem
AT johnstonerickyw theanticancereffectsofhdacinhibitorsrequiretheimmunesystem
AT westalisonc anticancereffectsofhdacinhibitorsrequiretheimmunesystem
AT smythmarkj anticancereffectsofhdacinhibitorsrequiretheimmunesystem
AT johnstonerickyw anticancereffectsofhdacinhibitorsrequiretheimmunesystem

Ejemplares similares